Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

From 1982 to January 1991 228 orthotopic liver transplantations (OLT) were performed in 213 patients with end-stage disease at the Vienna transplantation centre, 1st University Department of Surgery. 14 patients were serum HBV surface antigen (HBsAg) positive at the time of transplantation. In the first 4 patients only OLT was performed; postoperatively all grafts became reinfected and the patients developed chronic hepatitis. In a further series, immunoprophylaxis against hepatitis B virus reinfection was carried out with hyperimmuneglobulin. In 4 patients short-term immunoprophylaxis was performed; all of them were seronegative after OLT, but HBsAg ++reoccurred in the serum within 3-16 weeks after transplantation and all patients experienced reinfection of their graft. The 2 patients, who had been transplanted in a replicative state (HBeAg positive) showed a fatal course of hepatitis in the graft. Out of 6 patients given long-term immunoprophylaxis 3 cases showed stable liver function, without any signs of reinfection, and the HBsAg negative status remained for up to 19 months after transplantation. Since two patients displayed a HBV replicate status prior to transplantation, alpha interferon was administered preoperatively, which resulted in decreased serum HBV-DNA levels.
 ...
PMID:[Experiences with liver transplantation in hepatitis B antigen positive liver cirrhosis]. 175 57

We measured thyrotropin receptor antibodies in serum obtained from 2 groups of patients participating in clinical trials of recombinant interferon-alpha 2b for viral hepatitis. Group I: Patients with hepatitis B (N = 8), received interferon 5 x 10(6) units thrice weekly for 4 months. Group II: Patients with non-A, non-B hepatitis (N = 16) were randomized to receive interferon in a dose of either 0.25 x 10(6) or 3 x 10(6) U thrice weekly for 6 months and then crossed over to receive the other dosage schedule for a further 6 months. None of the patients developed thyrotoxicosis. Thyrotropin receptor antibody activity was detectable within the "normal range" (less than 10 U/l) in 6 patients prior to treatment. In Group I, thyrotropin receptor antibodies became detectable in 6 patients on treatment, in 4 of whom it was 10 U/l. In Group II, thyrotropin receptor antibody activity was unchanged on low-dose interferon, but on the higher dose became detectable in 9 patients, in 7 of whom it was greater than 10 U/l. We conclude that treatment with interferon is associated with the development of thyrotropin receptor antibodies in a large proportion of patients. It is possible that in some patients treated with higher doses of interferon the increase in thyrotropin receptor antibody activity may be sufficient to induce hyperthyroidism.
 ...
PMID:Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. 175 38

The behaviour of drug addicts and alcoholics leads to the cooperation of risk factors concerning the development of chronic hepatitis, liver cirrhosis and hepatocarcinoma. The authors evaluate the prevalence of infections from B, C and Delta virus among a group of 40 intravenous drug users and 40 alcoholics affering to a territorial centre for drug dependence located in Valtellina (Italy). The prevalence of at least one serum marker of virus B, C or Delta hepatitis results to be 85% among drug addicts and 17% among alcoholics. The prevalence of Anti-HCV in alcoholics results to be much lower than found in former works. For what concerns the hepatitis B virus, 68% of the drug addicts and 10% of the alcoholics had at least one positive serum marker. The hepatitis B seronegative patients underwent vaccination with a recombinant-DNA vaccine. Those affected by chronic C hepatitis have been treated with alpha-recombinant interferon. All of the patients underwent health education, psychotherapy and drug-addiction therapy for a period of 8 months. These strategies in prevention and therapy aim to the reduction over the years of the incidence of chronic hepatitis liver cirrhosis and hepatocarcinoma among intravenous drug users and alcoholics.
 ...
PMID:[Prevalence of liver damage in alcoholics and drug addicts]. 176 28

The genes for interferon (IFN) alpha, IFN gamma, IL-1 beta, IL-6, and TNF alpha were transcribed at readily detectable levels both in liver biopsies from individuals with normal liver function and in samples of normal viable liver taken for transplantation. These results provided evidence for the concept that such multifunctional cytokines play a role in homeostasis in normal human tissues. In normal human liver, in situ hybridization studies showed that, in the absence of a detectable inflammatory response, both hepatocytes and mononuclear cells exhibited a similar degree of expression of IL-6 mRNA in keeping with the finding that IL-6 is produced by cells of different lineages. The levels of IL-1, IL-6, and TNF mRNA were found to be markedly reduced in extracts of the livers of patients with primary biliary cirrhosis and other forms of autoimmune liver disease at a time when extensive liver lesions were apparent, compared to the levels of expression of these cytokines in the livers of normal individuals. The reduced expression of IL-1, IL-6, and TNF mRNAs appeared to be a specific effect and not due to a general reduction in RNA synthesis as the IFN alpha, IFN gamma and actin mRNAs were expressed at similar levels in both normal and diseased livers. The levels of IL-1 beta, IL-6, and TNF mRNAs were also reduced in samples of liver from a patient with a drug induced fulminant hepatitis suggesting that this specific pattern of altered cytokine gene expression was characteristic of the advanced stage of severe liver disease.
 ...
PMID:Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease. 177 64

Alpha interferon is the only effective therapy in patients with chronic non-A, non-B hepatitis. Alpha interferon administration during 6 months, in a dosage of 3 millions units, three times per week, induces a complete response defined by the normalisation of transaminases in about 50% of the patients. The normalisation of transaminases is correlated to an improvement of liver histologic activity. A relapse, with the re-increase of transaminases, is often observed after withdrawal of interferon. One year after therapy, less than 20% of the patients treated have a sustained complete response defined by persistently normal transaminases. Studies are in progress about the efficacy of higher dosage or longer duration of alpha interferon administration.
 ...
PMID:[Interferon and chronic non-A, non-B hepatitis: status of the problem]. 179 40

Post-transfusion hepatitis (PTH) is a major problem in patients with acute leukemias requiring blood products during induction or consolidation therapy. In fact, PTH causes delays of chemotherapy with major violations in the timing of protocols. In order to assess the efficacy and safety of a short course of alpha-interferon (alpha-IFN) in inducing early remission of PTH, we treated seven patients who developed acute hepatitis during a post-remissional phase of AML. Patients received 3 MU of alpha-IFN i.m. three times weekly for one month. One patient stopped alpha-IFN at 2 weeks because of severe itching, after ALT normalization. Five out of 6 subjects normalized ALT within a mean time of two weeks. Minor side effects were observed in 2 cases. Three patients relapsed within eight weeks after stopping alpha-IFN. They underwent a second remission upon treatment with the same schedule. All patients continued their treatment protocol for AML without delay.
 ...
PMID:Recombinant interferon alpha-2B for acute post-transfusion hepatitis in acute myeloid leukemia. 180 50

To assess the efficacy of therapy with alfa Interferon in chronic hepatitis C (NANB), 18 patients were enrolled in an open trial. Eleven were males and 7 females with a mean age of 43 years. Interferon alfa 2b was used in titrated doses for 9 months and the treatment was started with 5 m.U./Ti. During therapy, the patients were evaluated clinically and biochemically. A liver biopsy was done within 3 months after the completion of treatment. The serum alanine aminotransferase (ALT) level 1 became completely normal in 11 patients (61%) at 3 months of therapy and a partial response was seen in 3 (16%). At the 6 months the ALT sustained normal in 10 patients (55%) and a partial response was seen in 5 (27.7%). Four out of 7 patients (57%) who completed the therapy had complete response and 2 (28.5%) a partial response. From 5 patients who completed the follow-up, 3 (60%) had a relapse of ALT levels. A low level of ALT at the beginning of treatment had a predictive value of response to the therapy (P less than 0.05). The side effects of interferon therapy were usually mild. Fever, myalgias and headaches were seen in 72% of patients in the first two weeks of therapy. No haematological alterations were seen. We conclude that a 9 month course of interferon therapy is effective in controlling disease activity in many patients with chronic NANB hepatitis. However, the high relapse rate suggest that future studies should establish the optimal dose and duration of treatment to induce a complete resolution of the disease.
 ...
PMID:[Therapy of chronic non-A, non-B hepatitis with recombinant interferon alfa and factors that influence the response to the treatment]. 180 97

We studied the relations between HBV heterogeneity and different phases of HBV infection and disease in 145 HBsAg-positive carriers followed-up for 28 months (range 24-60 months). Viraemia was characterized for the relative prevalence of wild-type and HBeAg minus HBVs after HBV-DNA amplification by PCR using an oligonucleotide hybridization assay. HBeAg minus HBV was detected in 27% of immunotolerant HBV carriers, in 67% of patients with chronic hepatitis B (immunoelimination phase) and in 17% of HBsAg carriers with latent infection. Serum HBV-DNA and IgM anti-HBc became undetectable and ALT levels normalized, either spontaneously or after interferon therapy in 12 (36.3%) of 33 patients with an exclusive wild-type viraemia, but only in two (5.7%) of 35 patients with homogeneous HBeAg minus HBV (p = 0.005). An HBeAg minus viraemia higher than 20% was associated, in both HBeAg- and anti-HBe-positive patients, with HBV-induced liver disease and an unfavourable outcome of hepatitis. These findings suggest that surgence of HBeAg defective HBV is a virus strategy to survive under peculiar conditions dictated by the interplay between HBV and the host's immune system. The HBeAg/anti-HBe serological status is determined not only by the extent of virus replication and integration of HBV-DNA into cellular DNA but also by heterogeneity of HBV. The study of HBV heterogeneity in baseline sera of patients undergoing antiviral therapy appears to have a predictive value of the outcome of HBV infection in the single patient.
 ...
PMID:'e' antigen defective hepatitis B virus and course of chronic infection. 182 19

Hepatitis C virus antibody (anti-HCV) was assessed in serum samples from patients with non-A, non-B liver diseases using an Ortho HCV ELISA kit. In patients with posttransfusion hepatitis, anti-HCV was found in 89% and the interval between onset and anti-HCV seroconversion was 51 to 168 (mean 80) days. Anti-HCV remained positive with fluctuating serum GPT levels in 88% of the patients in whom anti-HCV seroconversion was observed. In chronic liver diseases, anti-HCV was found in 70 to 100%, being more common in patients who had a history of blood transfusion. The average interval between transfusion and detectable anti-HCV was 21.5 years. Anti-HCV was also found occasionally in patients having normalized serum GPT level after the onset, HBV carrier with posttransfusion hepatitis and patients with autoimmune hepatitis. Decreasing anti-HCV titer was noted with the normalization of serum GPT levels in the patients who received interferon therapy. These findings suggest that anti-HCV is closely associated with blood transfusion and HCV infection plays an important role in non-A, non-B liver diseases. The improvement of the current HCV assay system seems to contribute to further evaluation of the clinical entity of HCV infection.
 ...
PMID:[Detection of hepatitis C virus antibody in non-A non-B liver diseases]. 184 11

Chronic hepatitis may take the form of a hepatitis B infection, a delta virus infection, or a non-A, non-B hepatitis including hepatitis C. All the viruses involved are transmitted predominantly by parenteral or sexual routes. New insights into the structure of the hepatitis B virus (HBV) and the immune response mechanisms of the organism permit a clear definition of the replicative state of the virus, and allow predictions to be made about the outcome of the disease. Development of cirrhosis and hepatocellular carcinoma are the major complications associated with impaired life expectancy. Recently, the hepatitis C virus (HCV) was identified as the agent responsible for most cases of chronic non-A, non-B hepatitis. The development of an assay for the detection of HCV-antibodies facilitated the diagnosis of this type of hepatitis. Moreover, the use of screening tests for hepatitis B and hepatitis C in blood donors will decrease the risk of acquiring hepatitis via contaminated blood products. Treatment of chronic hepatitis B and C with alpha-interferon has shown promising results. However, the dosage schedule, the period of treatment, and the selection of patients needs to be evaluated in further studies.
 ...
PMID:Epidemiology, clinical course and treatment of chronic viral hepatitis. 185 Nov 29


<< Previous 1 2 3 4 5 6 7 8 9 10